From the authors

American Journal of Respiratory and Critical Care Medicine

Volumn 178, Issue 10, 2008, Pages 1091-1092

  Wedzicha, Jadwiga A ^a   Calverley, Peter M A ^b   Seemungal, Terence A ^c   Hagan, Gerry ^d   Ansari, Zainab ^d   Stockley, Robert A ^e  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; TIOTROPIUM BROMIDE;

ANALYTIC METHOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LETTER; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT WITHDRAWAL;

EID: 57349092996     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Wedzicha JA, Calverley PMA, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
2. Suissa S, Ernst P, Vandemheem KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:1-8.
3. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al.; for the Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium combination with placebo, salmeterol or fluticasone - salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555.
4. Lanes SF, Jara M. The INSPIRE study: influence of prior use and discontinuation of inhaled corticosteroids [Letter to the Editor]. Am J Respir Crit Care Med 2008;178:543-544. [Reply by J. A. Wedzicha and colleagues on p. 544.]
5. Moher D, Schulz KF, Altman D; for the CONSORT Group. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
6. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-694.